← All trials
NCT06560333
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2026
- Primary completion
- Apr 30, 2027
- Completion date
- Feb 28, 2029
- First posted
- Aug 19, 2024
- Last posted
- Aug 21, 2024
- Enrollment
- 612
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eurofarma Laboratorios S.A.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.